A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation

Robert Craft, Jack Chavez, Stuart Bresee, Dale Wortham, Eli Cohen, Roger C. Carroll

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Flow cytometry, singlet platelet counting, and optical aggregation have been used to monitor clopidogrel and glycoprotein IIb/IIIa (GPIIb/IIIa) platelet antagonists. Optical aggregation is considered the gold standard, but neither it nor flow cytometry is convenient in larger-scale clinical studies or point-of-care systems. Singlet platelet counting, a point-of-care assay correlated with optical platelet aggregation, only provides a measurement of platelet function at a single point in time. The Trombelastograph is used to assay whole blood for thrombin-generated maximal clot-shear elasticity, referred to as the maximal amplitude (MA). Although platelet dysfunction, thrombocytopenia, and the in vitro effect of strong inhibitors such as IIb/IIIa antagonists can be observed, with thrombin generation milder platelet inhibitors cannot be assessed. We modified the Thromboelastograph assay, using reptilase and factor XIIIa, to form a clot, without thrombin generation, in heparinized whole blood. The resulting clot MA is dependent on added platelet agonists such as ADP or arachidonic acid, is sensitive to platelet antagonists, and provides a continuous measure of platelet function more analogous and better correlated with optical aggregation. This novel modification of the Thromboelastograph assay should prove to be a useful point-of-care whole-blood assay with which to monitor the effects of GPIIb/IIIa, ADP, and thromboxane A2-receptor- inhibiting drugs in patients.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalJournal of Laboratory and Clinical Medicine
Volume143
Issue number5
DOIs
StatePublished - Jan 1 2004

Fingerprint

Platelets
Platelet Aggregation
Assays
Blood Platelets
Agglomeration
Point-of-Care Systems
Platelet Aggregation Inhibitors
Thrombin
clopidogrel
Blood
Flow cytometry
Adenosine Diphosphate
Flow Cytometry
Batroxobin
Factor XIIIa
Prostaglandin H2 Receptors Thromboxane A2
Platelet Glycoprotein GPIIb-IIIa Complex
Elasticity
Arachidonic Acid
Thrombocytopenia

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

@article{3851961247ff4a8c8e3d6d15e777cfc6,
title = "A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation",
abstract = "Flow cytometry, singlet platelet counting, and optical aggregation have been used to monitor clopidogrel and glycoprotein IIb/IIIa (GPIIb/IIIa) platelet antagonists. Optical aggregation is considered the gold standard, but neither it nor flow cytometry is convenient in larger-scale clinical studies or point-of-care systems. Singlet platelet counting, a point-of-care assay correlated with optical platelet aggregation, only provides a measurement of platelet function at a single point in time. The Trombelastograph is used to assay whole blood for thrombin-generated maximal clot-shear elasticity, referred to as the maximal amplitude (MA). Although platelet dysfunction, thrombocytopenia, and the in vitro effect of strong inhibitors such as IIb/IIIa antagonists can be observed, with thrombin generation milder platelet inhibitors cannot be assessed. We modified the Thromboelastograph assay, using reptilase and factor XIIIa, to form a clot, without thrombin generation, in heparinized whole blood. The resulting clot MA is dependent on added platelet agonists such as ADP or arachidonic acid, is sensitive to platelet antagonists, and provides a continuous measure of platelet function more analogous and better correlated with optical aggregation. This novel modification of the Thromboelastograph assay should prove to be a useful point-of-care whole-blood assay with which to monitor the effects of GPIIb/IIIa, ADP, and thromboxane A2-receptor- inhibiting drugs in patients.",
author = "Robert Craft and Jack Chavez and Stuart Bresee and Dale Wortham and Eli Cohen and Carroll, {Roger C.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.lab.2004.01.011",
language = "English (US)",
volume = "143",
pages = "301--309",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation

AU - Craft, Robert

AU - Chavez, Jack

AU - Bresee, Stuart

AU - Wortham, Dale

AU - Cohen, Eli

AU - Carroll, Roger C.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Flow cytometry, singlet platelet counting, and optical aggregation have been used to monitor clopidogrel and glycoprotein IIb/IIIa (GPIIb/IIIa) platelet antagonists. Optical aggregation is considered the gold standard, but neither it nor flow cytometry is convenient in larger-scale clinical studies or point-of-care systems. Singlet platelet counting, a point-of-care assay correlated with optical platelet aggregation, only provides a measurement of platelet function at a single point in time. The Trombelastograph is used to assay whole blood for thrombin-generated maximal clot-shear elasticity, referred to as the maximal amplitude (MA). Although platelet dysfunction, thrombocytopenia, and the in vitro effect of strong inhibitors such as IIb/IIIa antagonists can be observed, with thrombin generation milder platelet inhibitors cannot be assessed. We modified the Thromboelastograph assay, using reptilase and factor XIIIa, to form a clot, without thrombin generation, in heparinized whole blood. The resulting clot MA is dependent on added platelet agonists such as ADP or arachidonic acid, is sensitive to platelet antagonists, and provides a continuous measure of platelet function more analogous and better correlated with optical aggregation. This novel modification of the Thromboelastograph assay should prove to be a useful point-of-care whole-blood assay with which to monitor the effects of GPIIb/IIIa, ADP, and thromboxane A2-receptor- inhibiting drugs in patients.

AB - Flow cytometry, singlet platelet counting, and optical aggregation have been used to monitor clopidogrel and glycoprotein IIb/IIIa (GPIIb/IIIa) platelet antagonists. Optical aggregation is considered the gold standard, but neither it nor flow cytometry is convenient in larger-scale clinical studies or point-of-care systems. Singlet platelet counting, a point-of-care assay correlated with optical platelet aggregation, only provides a measurement of platelet function at a single point in time. The Trombelastograph is used to assay whole blood for thrombin-generated maximal clot-shear elasticity, referred to as the maximal amplitude (MA). Although platelet dysfunction, thrombocytopenia, and the in vitro effect of strong inhibitors such as IIb/IIIa antagonists can be observed, with thrombin generation milder platelet inhibitors cannot be assessed. We modified the Thromboelastograph assay, using reptilase and factor XIIIa, to form a clot, without thrombin generation, in heparinized whole blood. The resulting clot MA is dependent on added platelet agonists such as ADP or arachidonic acid, is sensitive to platelet antagonists, and provides a continuous measure of platelet function more analogous and better correlated with optical aggregation. This novel modification of the Thromboelastograph assay should prove to be a useful point-of-care whole-blood assay with which to monitor the effects of GPIIb/IIIa, ADP, and thromboxane A2-receptor- inhibiting drugs in patients.

UR - http://www.scopus.com/inward/record.url?scp=2342489360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342489360&partnerID=8YFLogxK

U2 - 10.1016/j.lab.2004.01.011

DO - 10.1016/j.lab.2004.01.011

M3 - Article

VL - 143

SP - 301

EP - 309

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -